Comparative Pharmacology
Head-to-head clinical analysis: FINGOLIMOD HYDROCHLORIDE versus VELSIPITY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FINGOLIMOD HYDROCHLORIDE versus VELSIPITY.
FINGOLIMOD HYDROCHLORIDE vs VELSIPITY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sphingosine 1-phosphate receptor modulator; binds to S1P receptors (S1P1, S1P3, S1P4, S1P5) on lymphocytes, causing receptor internalization and preventing egress from lymph nodes, thereby reducing circulating lymphocyte counts.
Sphingosine 1-phosphate (S1P) receptor modulator; selectively binds to S1P receptor subtypes 1, 4, and 5, inhibiting lymphocyte egress from lymphoid tissues, thereby reducing circulating lymphocytes.
0.5 mg orally once daily
0.23 mg subcutaneously once weekly.
None Documented
None Documented
Terminal elimination half-life is approximately 6–9 days; due to extensive tissue distribution, steady-state is reached within 1–2 months of daily dosing.
Terminal elimination half-life is approximately 20 days. This long half-life allows for weekly oral dosing and requires a prolonged washout period before initiating other treatments.
Primarily hepatic metabolism (CYP4F2) with subsequent biliary/fecal elimination (81% of total clearance); renal excretion accounts for <2.5% of unchanged drug.
Primarily eliminated via biliary/fecal route (approximately 70% as unchanged drug) and renal excretion (approximately 30% as unchanged drug and metabolites, with less than 1% as unchanged drug in urine).
Category C
Category C
Sphingosine 1-Phosphate Receptor Modulator
Sphingosine 1-Phosphate Receptor Modulator